Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-877 dose-finding study in statin-treated patients with mixed dyslipidemia
NL-OMON40373Phase 2Active, not recruiting
- Sponsor
- Kowa Company, Ltd.
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pemafibrate in dyslipidemia and hypertriglyceridemia (7 arms), sponsored by Kowa Company, Ltd. Primary endpoints: Percent change in non-HDL cholesterol from baseline to Week 12, Percent change in triglycerides from baseline to Week 12 and 2 more. Started Dec 2013; status: active, not recruiting.
02
Drugs
pemafibrate
03
Conditions
dyslipidemiahypertriglyceridemia
Beyond the preview
Go deeper on NL-OMON40373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40373.